Elevance Health, Inc. (NYSE:ELV) Shares Sold by South Dakota Investment Council

South Dakota Investment Council decreased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,475 shares of the company’s stock after selling 800 shares during the period. South Dakota Investment Council’s holdings in Elevance Health were worth $12,013,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ELV. OFI Invest Asset Management acquired a new position in Elevance Health during the third quarter worth approximately $25,000. ORG Partners LLC acquired a new position in Elevance Health during the fourth quarter worth approximately $40,000. Orion Capital Management LLC purchased a new stake in Elevance Health during the third quarter worth approximately $46,000. Milestone Investment Advisors LLC purchased a new stake in Elevance Health during the third quarter worth approximately $51,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in Elevance Health during the fourth quarter worth approximately $56,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 0.1 %

NYSE ELV traded up $0.70 during trading hours on Tuesday, reaching $532.92. 796,340 shares of the company traded hands, compared to its average volume of 1,066,078. Elevance Health, Inc. has a 12 month low of $412.00 and a 12 month high of $539.11. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $123.86 billion, a PE ratio of 20.14, a PEG ratio of 1.16 and a beta of 0.78. The company has a 50 day moving average of $510.23 and a two-hundred day moving average of $485.10.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Thursday, April 18th. The company reported $10.64 EPS for the quarter, beating analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The firm had revenue of $42.27 billion for the quarter, compared to the consensus estimate of $42.49 billion. During the same period in the prior year, the firm posted $9.46 EPS. The firm’s revenue was up .9% compared to the same quarter last year. As a group, equities analysts expect that Elevance Health, Inc. will post 37.24 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be paid a dividend of $1.63 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.22%. Elevance Health’s dividend payout ratio (DPR) is 24.64%.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total transaction of $376,500.00. Following the transaction, the director now directly owns 9,109 shares in the company, valued at approximately $4,554,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ELV has been the subject of several research reports. Royal Bank of Canada boosted their price objective on shares of Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday. Barclays boosted their price objective on shares of Elevance Health from $584.00 to $621.00 and gave the stock an “overweight” rating in a research note on Friday. Truist Financial reiterated a “buy” rating and set a $600.00 price objective (up from $580.00) on shares of Elevance Health in a research note on Friday. Jefferies Financial Group boosted their price objective on shares of Elevance Health from $602.00 to $604.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $580.00 price objective on shares of Elevance Health in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $587.64.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.